698 reports of this reaction
1.6% of all CLOBAZAM reports
#9 most reported adverse reaction
STATUS EPILEPTICUS is the #9 most commonly reported adverse reaction for CLOBAZAM, manufactured by Lundbeck Pharmaceuticals LLC. There are 698 FDA adverse event reports linking CLOBAZAM to STATUS EPILEPTICUS. This represents approximately 1.6% of all 43,741 adverse event reports for this drug.
Patients taking CLOBAZAM who experience status epilepticus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
STATUS EPILEPTICUS is a less commonly reported adverse event for CLOBAZAM, but still significant enough to appear in the safety profile.
In addition to status epilepticus, the following adverse reactions have been reported for CLOBAZAM:
The following drugs have also been linked to status epilepticus in FDA adverse event reports:
STATUS EPILEPTICUS has been reported as an adverse event in 698 FDA reports for CLOBAZAM. This does not prove causation, but indicates an association observed in post-market surveillance data.
STATUS EPILEPTICUS accounts for approximately 1.6% of all adverse event reports for CLOBAZAM, making it a notable side effect.
If you experience status epilepticus while taking CLOBAZAM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.